{"id":911650,"date":"2025-11-19T09:36:23","date_gmt":"2025-11-19T14:36:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-and-cortechs-ai-extend-partnership-to-advance-quantitative-neuroimaging-and-strengthen-philips-leadership-in-precision-diagnostics-in-neurology\/"},"modified":"2025-11-19T09:36:23","modified_gmt":"2025-11-19T14:36:23","slug":"philips-and-cortechs-ai-extend-partnership-to-advance-quantitative-neuroimaging-and-strengthen-philips-leadership-in-precision-diagnostics-in-neurology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-and-cortechs-ai-extend-partnership-to-advance-quantitative-neuroimaging-and-strengthen-philips-leadership-in-precision-diagnostics-in-neurology\/","title":{"rendered":"Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips\u2019 leadership in precision diagnostics in neurology"},"content":{"rendered":"
\n

November 19, 2025<\/p>\n

Amsterdam, the Netherlands \u2013<\/b>Royal Philips<\/a> (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an extended partnership with Cortechs.ai<\/a>, a pioneer in quantitative neuroimaging solutions. Together, the companies will integrate Cortechs.ai\u2019s advanced AI-enabled neuroimaging analytics directly into Philips\u2019 MR systems [1], empowering clinicians with faster, more objective, and reproducible insights into brain health. The collaboration strengthens Philips\u2019 leadership in precision neuro diagnostics, combining Philips\u2019 next-generation MR technologies<\/a> with Cortechs.ai\u2019s AI-driven quantitative neuro imaging post processing software [1] to transform how neurological diseases are detected, monitored, and managed.<\/p>\n

Combining complementary expertise for smarter brain imaging<\/b>
Up to 25% [2] of all MR procedures are brain scans, and radiology departments face growing demand amid increasing staff shortages. At the same time, the number of patients with neurological conditions such as Alzheimer\u2019s disease, multiple sclerosis (MS), and brain tumors continue to rise globally. Current MR interpretation of neurodegenerative diseases or neuro oncology cases depends heavily on visual assessment, introducing variability and requiring significant expertise and time in an already overloaded system.<\/p>\n

Through this extended partnership, Philips and Cortechs.ai aim to deliver more standardized and data-driven imaging. By integrating quantitative analysis tools such as brain volumetrics, lesion quantification, and tumor tracking directly into the Philips MR imaging workflow [1], clinicians gain objective, numerical data alongside images \u2013 enabling faster, more consistent, and confident diagnoses.<\/p>\n

Empowering clinicians with precision and speed<\/b>
The integration of Cortechs.ai\u2019s NeuroQuant\u00ae solutions for Alzheimer\u2019s, MS and brain tumors within Philips\u2019 Smart Reading environment \u2013 a cloud-based AI platform that combines imaging, reading, and reporting directly on the MR systems [1] \u2013 marks a major step toward precision neuroimaging.<\/p>\n

With this integration, clinicians can automatically receive AI-generated quantitative reports within their standard MR workflow on the MR system or PACS, without adding extra steps for technologists. The zero-click process ensures quality-checked data and standardized outputs, helping radiologists interpret brain scans more objectively, faster and with greater confidence.<\/p>\n

\u201cBy extending our partnership with Cortechs.ai, we are accelerating the transition to fully quantitative, AI-powered neuroimaging,\u201d said Ioannis Panagiotelis, PhD, Business Leader, MRI, Philips. \u201cThis integration brings precision, reproducibility, and efficiency to neurological MR, helping clinicians make faster, more confident decisions for patients living with complex brain conditions.\u201d<\/p>\n

Driving productivity and improving care through AI<\/b>
Philips is driving productivity and improving care through deep AI integration that tackles some of healthcare\u2019s most pressing challenges \u2013 from workforce shortages to the growing demand for advanced diagnostics. By automatically generating quantitative reports within existing workflows, AI helps radiologists save time, improve consistency, and boost throughput. Objective numerical biomarkers enhance diagnostic accuracy, enabling more reproducible assessments and confident comparisons across time and sites. And by minimizing manual post-processing through automated, quality-controlled workflows, technologists can focus more on what matters most \u2013 delivering a better, more personalized patient experience.<\/p>\n

\u201cCortechs.ai\u2019s mission has always been to empower clinicians with actionable, quantitative insights,\u201d said Kyle Frye, Chief Executive Officer, Cortechs.ai. \u201cBy combining our advanced neuro analytics with Philips\u2019 leading MR platform and AI infrastructure, we\u2019re making it easier to personalize brain care and track neurological changes with precision.\u201d<\/p>\n

Setting a new standard in precision neuro diagnostics<\/b>
Cortechs.ai\u2019s \u00a0NeuroQuant\u00ae solutions are already available on Philips Advanced Visualization Workspace<\/a>. With this extended partnership, Philips reinforces its commitment to advancing the field of neurology \u2013 empowering healthcare providers to deliver better care for more people, in less time, with greater confidence.<\/p>\n

[1] The integration of Cortechs.ai\u2019s NeuroQuant\u00ae solutions on Philips MR systems via Smart Reading is works in progress and not available in any jurisdiction. Its future availability cannot be ensured. \u00a0NeuroQuant\u00ae is currently available via Advanced Visualization Workspace.
[2] Peter A. Rinck, Magnetic Resonance in Medicine \u2013 The Basics<\/i> (14th ed., revised 2025), \u201cMRI: Facts and Figures,\u201d available online at https:\/\/www.magnetic-resonance.org\/ch\/21-01.html<\/a>.
The opinions and clinical experiences presented herein are specific to the featured topic(s), are not linked to any specific patient and are for information purposes only. The medical experience(s) derived from these topics may not be predictive of all patients.\u00a0 Individual results may vary depending on a variety of patient-specific attributes and related factors. Nothing in this presentation is intended to provide specific medical advice or to take the place of written law or regulations.<\/p>\n

\n For further information, please contact:<\/b>\n <\/p>\n

Jayme Maniatis
Philips Global External Relations
Tel.: +1 (617) 894-8368
E-mail: jayme.maniatis@philips.com<\/a><\/p>\n

Cortechs.ai
Tel.: +1 858 459 9700
E-mail: info@cortechs.ai<\/a>\u00a0\u00a0<\/p>\n

\n About Royal Philips<\/b>\n <\/p>\n

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people\u2019s health and well-being through meaningful innovation. Philips\u2019 patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.<\/p>\n

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at\u00a0www.philips.com\/newscenter<\/a>.<\/p>\n

\n About Cortechs.ai<\/b>
\n
Cortechs.ai is a leader in AI applications in radiology. Cortechs.ai uses cutting-edge technologies in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, healthier lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai\u2019s industry-leading brain imaging software provides radiologists, neurologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective way to quantify brain structures for assessing Alzheimer\u2019s disease, epilepsy, multiple sclerosis, brain trauma, and other brain abnormalities. The company has FDA-cleared products for use in helping the diagnosis and follow-up of neurodegenerative and traumatic brain conditions, as well as prostate cancer. Please visit www.cortechs.ai<\/a> for further information and follow us on Twitter, LinkedIn, and Facebook.<\/p>\n

\n Attachment<\/strong>\n <\/p>\n